At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Nov 5, 2026 at 16:30 ET
BioAge reported Q3 2026 net loss of $33.5M ($0.73/share), wider than the $20.2M loss a year ago, as R&D spending surged to $30.2M to support Phase 2 trials of BGE-102. The company dosed the first patient in the QUELL-DME trial and completed enrollment in QUELL-CV, with topline data from QUELL-CV expected in Q4 2026. Cash of $352.3M is expected to fund operations through 2029.
- Net loss of $33.5M ($0.73/share) vs $20.2M ($0.56/share) in Q3 2025
- Collaboration revenue $0.3M, down from $2.1M a year ago
- R&D expenses $30.2M, up 63% from $18.5M, driven by BGE-102 clinical costs
- Cash, cash equivalents and marketable securities $352.3M as of Sep 30, 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access